Julie M. Vose, MD

Julie M. Vose, MD, MBA, professor and chief of the Division of Oncology and Hematology; and the George and Peggy Payne Distinguished Chair in Oncology at University of Nebraska Medical Center/Nebraska Medicine

Articles

Dr Vose on the Durability of Response to Epcoritamab Monotherapy in DLBCL

June 24th 2025

Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL

April 2nd 2025

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Dr Vose on the Safety of Epcoritamab in Relapsed/Refractory LBCL

March 12th 2025

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Dr Vose on the Investigation of Epcoritamab in Relapsed/Refractory Follicular Lymphoma

June 11th 2024

Julie M. Vose, MD, MBA, discusses the investigation of epcoritamab in relapsed/refractory follicular lymphoma.

Dr Vose on Mitigating Epcoritamab-Associated CRS and Neurologic Toxicities in R/R DLBCL

January 30th 2024

Julie M. Vose, MD, MBA, discusses the mitigation of toxicities with epcoritamab in an optimization cohort of patients with relapsed/refractory DLBCL.

Dr Vose on the SYMPHONY-1 Trial in Relapsed/Refractory Follicular Lymphoma

October 18th 2023

Julie M. Vose, MD, MBA, discusses the investigation of tazemetostat vs placebo when given in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma in the phase 3 SYMPHONY-1 study.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Vose on the Potential Utility of CAR T-Cell Therapy Across Non-Hodgkin Lymphoma

August 20th 2021

Julie M. Vose, MD, MBA, discusses the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma paradigm.

Dr. Vose on Future Research Efforts With CAR T-Cell Therapy in Lymphoma

August 11th 2021

Julie M. Vose, MD, MBA, discusses future research efforts with CAR T-cell therapy in lymphoma.

Dr. Vose on Acalabrutinib/Pembrolizumab Combo in DLBCL

June 19th 2019

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Dr. Vose Discusses the Importance of Genomic Analysis in NHL

July 18th 2018

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

x